No profile data available.
Dr. Reddy's Laboratories Limited (RDY) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Hyderabad, India, with about 27,527 full-time employees.
It reported revenue of 335.93 billion INR for fiscal year 2026, up 3.2% from fiscal year 2025, and net income of 41.96 billion INR. In Q1 2027 (the quarter ended June 30, 2026) revenue was 80.71 billion INR, down 5.6% from a year before. Its largest business segment, Global Generics, brought in 87% of segment revenue in fiscal year 2026; Others was the largest region with 35%. Its market capitalization was $10.40 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2026; market data as of October 9, 2026.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.
Dr. Reddy's Laboratories reported 335.93 billion INR in revenue for fiscal year 2026, up 3.2% from 325.54 billion INR in fiscal year 2025. In Q1 2027 revenue was 80.71 billion INR.
Global Generics, with 299.03 billion INR or 87% of segment revenue in fiscal year 2026. Next: Pharmaceutical Services and Active Ingredients (12%) and Others (1%).
Others: 35% of revenue by region in fiscal year 2026, followed by United States (35%).
$10.40 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Haleon plc (HLN), Royalty Pharma plc (RPRX), Viatris Inc. (VTRS), Ionis Pharmaceuticals, Inc. (IONS).